UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~March 245, 2018

ANTHERA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-34637	~~20-1852016~~	20-1852016
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	~~(I.R.S. Employer Identification No.)~~	(I.R.S. Employer Identification No.)
25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 32.~~01. Notice~~02 Results of ~~Delisting~~Operations orand ~~Failure~~Financial ~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Conditions.

On ~~January~~March 245, 2018, Anthera Pharmaceuticals, Inc. (the “Company”) ~~received~~issued ~~formal notification from The NASDAQ Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) had determined to grant the Company’s request for the transfer of~~ its ~~listing~~fourth ~~from~~quarter ~~The~~and ~~Nasdaq~~year ~~Global~~ended ~~Market~~December ~~to The Nasdaq Capital Market~~31, ~~pursuant~~2017 topress ~~an extension through May 14, 2018 to evidence compliance with all applicable requirements for continued listing on Nasdaq~~release. A ~~The~~copy ~~Company is taking definitive steps to timely evidence compliance with the terms~~ of the ~~Panel’s~~press ~~decision;~~release ~~however,~~is ~~there~~furnished ~~can~~herewith beas noExhibit ~~assurance that it will be able to do so~~99.1

AsItem previously disclosed, on November 17, 2017, the Company received written notice from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that, due to the Company’s continued non-compliance with Listing Rule 5450(b)(1)(A) (the “Minimum Stockholders’ Equity Rule”) requirement for continued listing on The Nasdaq Global Market, the Staff had determined to delist the Company’s securities from The Nasdaq Global Market unless the Company timely requested a hearing before the Panel9.01 ~~The~~Financial ~~Panel’s~~Statements ~~decision,~~and dated January 24, 2018, follows the Company’s hearing before the Panel, at which it requested the transfer of its listing to The Nasdaq Capital Market pursuant to an extension through May 14, 2018 to evidence full compliance with all applicable requirements for the continued listing on NasdaqExhibits.

~~The~~(d) ~~Company issued a press release regarding the notice received from the Staff. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.~~Exhibits

Item 9.01 Exhibits

Exhibit No.			Description
99.1		Press Release dated March 5, 2018

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated January 25, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 25, 2018	Anthera Pharmaceuticals, Inc.
Date: March 5, 2018	Anthera Pharmaceuticals, Inc.
	By:	/s/ J.May ~~Craig Thompson~~Liu
		J. Craig Thompson
		May Liu Senior Vice President, Finance and Administration (Principal Accounting Officer)
		President and Chief Executive Officer

Filing Compare · Anthera Pharmaceuticals Inc